TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer.

ABSTRACT:

Background

Resistance or even hyper-progression to immune checkpoint inhibitors (ICIs) manifesting as accelerated disease progression or death has impeded the clinical use of ICIs. The transforming growth factor beta (TGFβ) receptor pathway has been identified in contributing to immune dysfunction, which might be associated with resistance to ICIs. We aimed to explore the role of TGFβ in the resistance to ICIs in non-small cell lung cancer (NSCLC) in this study.

Methods

Public cohorts with patients treated with ICIs or chemotherapy including POPLAR/OAK (n = 853), MSKCC (n = 1662) and Van Allen (n = 57) and TCGA (n = 3210) cohorts were obtained and analyzed.

Results

The expression of immune-checkpoint related genes, including programmed d

SUBMITTER: Li T 

PROVIDER: S-EPMC8366138 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature